how does glp 1 help type 2 diabetes GLP-1 receptor agonists are increasingly used to treat and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal GLP-1 Therapy for Type 2

10.1254/jphs.fp0072161 65 KolovratM.GojkovicS.KrezicI.MalekinusicD.VrdoljakB.Kasnik KovacK.et al (2020)

New York State Department of Health, Medicaid preferred drug program Wegovy is FDA-approved for chronic weight management (BMI 30+, or 27+ with a weight-related comorbidity) and for cardiovascular risk reduction in adults with established CVD it is a weight-loss and CV drug, not a diabetes drug

(Kind of like cute boots, but not in a good way.) In fact, nausea is an unpleasant side effect that affects up to 50% of GLP-1 users

The peptide promotes fatty acid oxidation in skeletal muscle, enhancing the utilization of lipids as an energy source while sparing glucose for other metabolic processes